Latest Vesicular stomatitis virus Stories
Giving low doses of a particular targeted agent with a cancer-killing virus might improve the effectiveness of the virus as a treatment for cancer.
Researchers from Yale University School of Medicine have demonstrated that vesicular stomatitis virus (VSV) is highly competent at finding, infecting, and killing human melanoma cells, both in vitro and in animal models, while having little propensity to infect non-cancerous cells.
Mayo Clinic researchers have trained mouse immune systems to eradicate skin cancer from within, using a genetic combination of human DNA from melanoma cells and a cousin of the rabies virus.
A new study turns the well established theory that antibodies are required for antiviral immunity upside down and reveals that an unexpected partnership between the specific and non-specific divisions of the immune system is critical for fighting some types of viral infections.
Cancer is one of the most common causes of death in humans.
Oncolytic virology uses live viruses to sense the genetic difference between a tumor and normal cell.
Therapeutic lentiviral vectors are emerging as vital tools for molecular medicine as evidenced by the growing number of clinical trials using these vector systems.
Vesicular stomatitis virus, or VSV, has long been a model system for studying and understanding the life cycle of negative-strand RNA viruses, which include viruses that cause influenza, measles and rabies.
Vesicular stomatitis virus (VSV) is a virus in the family Rhabdoviridae. Rabies is in the same family. VSV infects insects and animals and is important to farmers in certain regions of the world where it can infect cattle. It is a common laboratory virus used for studying the Rhabdoviridae family and viral evolution. It is the prototypic member of the vesiculovirus genera of the Rhabdovirus family. The genome is a single molecule of negative-sense RNA that encodes five major proteins.
- Emitting flashes of light; glittering.